H.C. Wainwright maintained a positive stance on Esperion Therapeutics (NASDAQ:ESPR) shares, reaffirming a Buy rating and a price target of $16.00. According to InvestingPro data, analyst targets for ...
JMP Securities lowered the firm’s price target on Esperion (ESPR) to $4 from $7 and keeps an Outperform rating on the shares. JMP updated its ...
JMP Securities adjusted its price target for Esperion Therapeutics (NASDAQ:ESPR) shares, lowering it to $4.00 from the previous $7.00. Currently trading at $1.86, the stock sits well below analyst ...
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Incyte (INCY – Research Report), Enanta Pharmaceuticals ...
Jan. 09, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will host a virtual key opinion leader (KOL) event to discuss the real-world use of NEXLETOL® (bempedoic acid) ...
At the beginning of May, Pfizer spun back out Esperion Therapeutics, which it had originally purchased for $1.3 billion in March 2004. Since the acquisition, most of Esperion's promising pipeline ...
Cantor Fitzgerald analyst Kristen Kluska initiated coverage of Esperion (ESPR) with an Overweight rating and $8 price target. The company markets the oral ATP-citrate lyase inhibitors, Nexletol ...
For Dr. JoAnne Foody, the Chief Medical Officer at Esperion, solving this cardiovascular care gap is a personal passion. It’s why she’s excited about Esperion’s recent CLEAR Outcomes study ...
Esperion Therapeutics, Inc. is a pharmaceutical company, which engages in the development and commercialization of oral therapies for elevated low-density lipoprotein cholesterol. The firm offers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback